Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

Background Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line
setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of …

Simple Summary We evaluated the efficacy and safety of molecular-targeted therapies
(MTTs) in 29 patients who discontinued the combination therapy of nivolumab plus …

Objectives To investigate the efficacy and safety of first‐line nivolumab plus ipilimumab for
patients treated with metastatic renal cell carcinoma. Methods We retrospectively evaluated …

Importance Recently, new drugs have been approved for the first-line treatment of metastatic
renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall …

Background Nivolumab plus ipilimumab combination therapy is one of the standard
therapies for untreated renal cell carcinoma patients with an International Metastatic Renal …

Background It remains unclear how early treatment interruption of nivolumab plus
ipilimumab due to immune-related adverse events affects the outcome of previously …

Introduction. Immune checkpoint inhibitors (ICI) have been approved for front‐line therapy in
metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and …

Introduction Ipilimumab plus nivolumab was associated with a survival benefit in a phase III
clinical trial of first-line treatment for metastatic renal cell carcinoma (mRCC). In this study …

Background Long-term follow-up data regarding treatment outcomes of nivolumab plus
ipilimumab combination therapy for advanced renal cell carcinoma as a first-line therapy are …